Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.

导出原文传递

翻译打印收藏纠错

作者： Véronique,Diéras ^[1] ; Hyo S,Han ^[2] ; Bella,Kaufman ^[3] ; Hans,Wildiers ^[4] ; Michael,Friedlander ^[5] ; Jean-Pierre,Ayoub ^[6] ; Shannon L,Puhalla ^[7] ; Igor,Bondarenko ^[8] ; Mario,Campone ^[9] ; Erik H,Jakobsen ^[10] ; Mathilde,Jalving ^[11] ; Cristina,Oprean ^[12] ; Marketa,Palácová ^[13] ; Yeon Hee,Park ^[14] ; Yaroslav,Shparyk ^[15] ; Eduardo,Yañez ^[16] ; Nikhil,Khandelwal ^[17] ; Madan G,Kundu ^[17] ; Matthew,Dudley ^[17] ; Christine K,Ratajczak ^[17] ; David,Maag ^[17] ; Banu K,Arun ^[18]

作者单位： Institut Curie, Paris, France; Breast Oncology, Centre Eugène Marquis, Rennes, France. Electronic address: v.dieras@rennes.unicancer.fr. ^[1] Moffitt Cancer Center, Tampa, FL, USA. ^[2] Tel-Aviv University, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel. ^[3] Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium. ^[4] Prince of Wales Clinical School UNSW and Prince of Wales Hospital, Sydney, NSW, Australia. ^[5] Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada. ^[6] UPMC Cancer Centers, Pittsburgh, PA, USA. ^[7] Dnipropetrovsk Medical Academy, City Clinical Hospital Number 4, Dnipro, Ukraine. ^[8] Institut de Cancérologie de l'Ouest Saint-Herblain, France. ^[9] Vejle Hospital/Lillebaelt Hospital, Vejle, Denmark. ^[10] University Medical Center Groningen, University of Groningen, Groningen, Netherlands. ^[11] University of Medicine and Pharmacy Timisoara and Oncomed SRL, Timisoara, Romania. ^[12] Masaryk Memorial Cancer Institute, Brno, Czech Republic. ^[13] Samsung Medical Center, Seoul, South Korea. ^[14] Lviv State Regional Treatment and Diagnostic Oncology Center, Lviv, Ukraine. ^[15] Universidad de la Frontera, Temuco, Chile. ^[16] AbbVie, North Chicago, IL, USA. ^[17] The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[18]